Semaglutide (Ozempic, Rybelsus), a novel GLP-1 agonist currently undergoing two phase-3 clinical trials in AD patients (NCT04777396 and NCT04777409), has demonstrated positive effects on AD pathology in a 3xTg-AD mouse model, including improved cognition and glucose metabolism (Wang et al. 2023). The gene discussed is GCG; the disease is Alzheimer disease.